Only about 30% of patients with distant breast cancer in the United States survive five years, yet 31% of diagnoses are still made at that stage. Breast cancer is the most commonly diagnosed cancer among women worldwide and causes 15.5% of cancer deaths among women globally. This article gathers the key figures on incidence, survival, risk, treatment outcomes, and research funding.
Key Takeaways
- 5-year relative survival for distant breast cancer is about 30% (United States)
- 31% of women diagnosed with breast cancer in the United States are diagnosed with distant stage disease (SEER summary stage distribution, recent years)
- Breast cancer is the most commonly diagnosed cancer among women worldwide
- In 2020, breast cancer accounted for 7.8% of all cancer deaths worldwide (both sexes) (GLOBOCAN 2020 estimate used in IARC fact sheet).
- BRCA2 pathogenic variants are associated with an estimated 45% to 69% lifetime risk of breast cancer.
- The National Comprehensive Cancer Network (NCCN) guideline-recommended surveillance after mastectomy includes follow-up visits every 3–6 months for 1–3 years in many cases (frequency stated in guidance).
- In the HERA trial, 1-year trastuzumab treatment improved disease-free survival compared with observation at a median follow-up reported in the publication.
- In the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, HER2-targeted therapy reduced breast cancer mortality by 25% in HER2-positive early disease.
- In the US, Medicare spending on breast cancer services exceeded $20 billion in 2015 (Medicare claims-based estimates reported in the paper).
- The NCI Center for Cancer Research reported that it funded multiple breast cancer–relevant grants within its intramural programs during FY2022 (reported in intramural funding overview tables).
- The Susan G. Komen organization reported total revenue of $675.0 million in 2023 (audited financial statements).
- The US NIH awarded $2.0 billion in breast cancer–related funding in 2022 based on NIH RePORTER query results for “breast cancer” (RePORTER funding totals methodology used by NIH).
With distant-stage survival near 30 percent and breast cancer causing millions of deaths, early detection and targeted care are critical.
Related reading
01 · Category
Epidemiology5 stats
01
5-year relative survival for distant breast cancer is about 30% (United States)
02
31% of women diagnosed with breast cancer in the United States are diagnosed with distant stage disease (SEER summary stage distribution, recent years)
03
Breast cancer is the most commonly diagnosed cancer among women worldwide
04
Breast cancer represents 15.5% of all cancer deaths among women worldwide (2020)
05
In the United Kingdom, breast cancer caused 11,748 deaths in 2022
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, breast cancer is widespread and deadly worldwide, with it being the most commonly diagnosed cancer among women and accounting for 15.5% of all female cancer deaths, while in the US only about 30% of women survive 5 years after distant stage disease.
02 · Category
Global Burden1 stats
01
In 2020, breast cancer accounted for 7.8% of all cancer deaths worldwide (both sexes) (GLOBOCAN 2020 estimate used in IARC fact sheet).
Interpretation
Global Burden Interpretation
In the global burden picture of breast cancer, the disease drove 7.8% of all worldwide cancer deaths in 2020, showing it remains a major share of cancer mortality across both sexes.
03 · Category
Epidemiology & Risk1 stats
01
BRCA2 pathogenic variants are associated with an estimated 45% to 69% lifetime risk of breast cancer.
Interpretation
Epidemiology & Risk Interpretation
For the Epidemiology and Risk category, BRCA2 pathogenic variants translate into a notably high lifetime breast cancer risk estimated at 45% to 69%, underscoring the strong genetic risk gradient for affected individuals.
More related reading
04 · Category
Treatment & Outcomes10 stats
01
The National Comprehensive Cancer Network (NCCN) guideline-recommended surveillance after mastectomy includes follow-up visits every 3–6 months for 1–3 years in many cases (frequency stated in guidance).
02
In the HERA trial, 1-year trastuzumab treatment improved disease-free survival compared with observation at a median follow-up reported in the publication.
03
In the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, HER2-targeted therapy reduced breast cancer mortality by 25% in HER2-positive early disease.
04
In the OlympiA trial, adjuvant olaparib improved overall survival versus placebo with a hazard ratio reported at the time of analysis.
05
In the MonarchE trial, adjuvant abemaciclib plus endocrine therapy improved invasive disease-free survival versus endocrine therapy alone in node-positive, high-risk, HR+/HER2− early breast cancer (hazard ratio reported).
06
In the NATALEE trial, adjuvant ribociclib plus endocrine therapy improved invasive disease-free survival versus endocrine therapy alone in early HR+/HER2− breast cancer (hazard ratio reported).
07
In the IMpassion130 trial, addition of atezolizumab to nab-paclitaxel improved progression-free survival and overall survival in PD-L1–selected metastatic triple-negative breast cancer (clinical benefit quantified).
08
In the KEYNOTE-522 trial, pembrolizumab plus chemotherapy increased pathological complete response rates versus chemotherapy alone in early triple-negative breast cancer (absolute percentage and comparison reported).
09
In the KEYNOTE-355 trial, pembrolizumab plus chemotherapy improved overall survival versus chemotherapy alone in previously untreated advanced triple-negative breast cancer with PD-L1 expression (hazard ratio reported).
10
In the EBCTCG 2011 meta-analysis, 5 years of tamoxifen reduces annual breast cancer mortality by about one-third for breast cancer patients whose tumors are ER-positive (mortality reduction estimate reported).
Interpretation
Treatment & Outcomes Interpretation
Across major Treatment and Outcomes studies, newer adjuvant and targeted strategies show clear benefits over standard approaches, with trials like HERA and EBCTCG demonstrating improved survival outcomes and additional options such as olaparib and CDK4 and 6 inhibitors further raising the odds of better disease-free or overall survival for appropriate breast cancer patients.
05 · Category
Cost & Access1 stats
01
In the US, Medicare spending on breast cancer services exceeded $20 billion in 2015 (Medicare claims-based estimates reported in the paper).
Interpretation
Cost & Access Interpretation
In the Cost and Access context, Medicare spending on breast cancer services in the US topped $20 billion in 2015, underscoring the enormous financial scale of care access through public coverage.
06 · Category
Research & Funding3 stats
01
The NCI Center for Cancer Research reported that it funded multiple breast cancer–relevant grants within its intramural programs during FY2022 (reported in intramural funding overview tables).
02
The Susan G. Komen organization reported total revenue of $675.0 million in 2023 (audited financial statements).
03
The US NIH awarded $2.0 billion in breast cancer–related funding in 2022 based on NIH RePORTER query results for “breast cancer” (RePORTER funding totals methodology used by NIH).
Interpretation
Research & Funding Interpretation
Across the Research and Funding landscape, federal investment stands out with NIH awarding $2.0 billion for breast cancer in 2022 while Komen reported $675.0 million in 2023 revenue and the NCI Center for Cancer Research continued funding multiple intramural breast-cancer relevant grants in FY2.
report visual · Comparison
Breast cancer outcomes and burden: survival vs stage vs mortality share
Distant-stage breast cancer has low 5-year survival, while distant-stage accounts for a large share of diagnoses and breast cancer remains a substantial fraction of cancer deaths worldwide.
31% of women diagnosed with breast cancer in the United States are diagnosed with distant stage disease (SEER summary st31%
5-year relative survival for distant breast cancer is about 30% (United States)
30%
Breast cancer represents 15.5% of all cancer deaths among women worldwide (2020)
15.5%
In 2020, breast cancer accounted for 7.8% of all cancer deaths worldwide (both sexes) (GLOBOCAN 2020 estimate used in IA
7.8%
source-verifiedseer.cancer.gov · gco.iarc.fr2020
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Breast Cancer Research Statistics. Gitnux. https://gitnux.org/breast-cancer-research-statistics
MLA
Gabrielle Fontaine. "Breast Cancer Research Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-research-statistics.
Chicago
Gabrielle Fontaine. 2026. "Breast Cancer Research Statistics." Gitnux. https://gitnux.org/breast-cancer-research-statistics.
Sources & references
21 datasets cited across this report · attribution is report-level
+10 additional datasets cited (not shown individually)